Aragen Bioscience, a Contract Research Development and Manufacturing Organization (CRDMO) for small molecules and biologics, and Getinge, a Swedish life sciences service provider, announced the successful validation of latter’s Single-Use Production Reactors (SUPR) for large-scale recombinant antibody production. This collaboration combines Aragen’s biopharmaceutical manufacturing expertise and Getinge’s single-use technology, that aims to enable seamless production of large-scale batches. 
 
 The validation study was conducted at Aragen’s state-of-the-art R&D facility in Morgan Hill, CA. It demonstrated the SUPR Bioreactor’s performance in generating high-quality recombinant antibodies. The reactor is designed to be a single-use alternative to traditional stainless-steel bioreactors at the pilot and production scale. This allows the upstream process to continue from research to production with one trusted single-use platform. R&D and process optimization performed in the AppliFlex ST or Applikon Bio can now be scaled up using the SUPR. 
 
 “We are thrilled to have collaborated with Getinge on this validation study This partnership showcases our commitment to providing our clients with cutting-edge technology and proven capabilities to accelerate their drug development programs,” said Dr. Subodh Deshmukh, CEO, Aragen Bioscience. “Getinge’s 50L and 250L single-use bioreactor platforms are now available at Aragen to support the growing demand for large-scale recombinant antibody production.” 
 
Timo Walvoort, Director of Research & Development, Getinge said, “The collaboration with Aragen has been instrumental in the development of this best-in-class, next generation, single-use production bioreactor system. Through closely working together, we have developed the world’s first single-use true bioreactor, with unparalleled ease-of-use. I look forward to many more fruitful collaborations with our friends at Aragen.”